2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 655

Hydroxycholorquine Is Cardioprotective in an In Vivo Rat Model of Myocardial Ischaemic Reperfusion Injury
Abstract Number: 1922

Hydroxylchloroquine Use Is Associated with Decreased Soluble TNF Receptor Levels in SLE Patient Samples
Abstract Number: 1276

Hyperglycemia and Risk of Osteoarthritis
Abstract Number: 2074

Hypervigilance and FMS
Abstract Number: 2693

Hyporesponsiveness to TLR9 in Term of Cytokines Production By B Cells in SLE-Patients
Abstract Number: 1201

Hypoxia Modulates Peptidyl Arginine Deiminase 4 Activity and Neutrophil Extracellular Trap Formation
Abstract Number: 1898

Identification of “autoinflammatory interferonopathies”? a New Class of Autoinflammatory Conditions?
Abstract Number: 1844

Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data
Abstract Number: 1293

Identification of an Inflammation-Driven Phenotype of Osteoarthritis By Quantification of Synovial Inflammation Ex Vivo and in Serum from Patients
Abstract Number: 983

Identification of Annexin A2 As an Autoantigen in Rheumatoid Arthritis and in Lyme Arthritis
Abstract Number: 2956

Identification of Autoimmune Functional Variants Under Positive Selection in the Gullah African American Population of South Carolina
Abstract Number: 468

Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients
Abstract Number: 2097

Identification of Diagnostic and Activity Metabolomic Urine Biomarkers in Six Immune-Mediated Inflammatory Diseases
Abstract Number: 652

Identification of Eat-2 As a Lupus Susceptibility Gene in New Zealand Black (NZB) Mice That Regulates Dendritic Cell Function
Abstract Number: 1131

Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].